Comparison of Accelerated Intermittent Theta Burst Stimulation vs High Frequency Transcranial Magnetic Stimulation (Hf-rTMS) on Cognitivesymptoms in Treatment-resistant Schizophrenia
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Study ID
- NCT07445620
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Psychosis
- Schizophrenia Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- Accelerated iTBS — DEVICE* Participants will receive aITBS using 100X transcranial magnetic stimulator with 70 mm active cooled figure-of-eight coil * Parameters: 3 pulses at 50 Hz bursts, 2 sec on/10 sec off, 3 minutes per session * Dosage: 1800 pulses per day (3 rounds separated by 15 min), 5 days/week for 4 weeks
- High-Frequency rTMS — DEVICE* Participants will receive HF-rTMS using 100X transcranial magnetic stimulator with 70 mm active cooled figure-of-eight coil * Parameters: 20 Hz pulses, 20 minutes, 4 sec per second, intertrain interval 20 sec, 110% RMT * Dosage: 5 sessions per week for 4 weeks
- Sham rTMS — DEVICE* Participants will receive sham stimulation using identical-appearing sham coil * Same session schedule and positioning as active groups but without therapeutic magnetic field
Study Details
This randomized, double-blind, sham-controlled trial compares three brain stimulation approaches-accelerated intermittent theta burst stimulation (aITBS), high-frequency repetitive transcranial magnetic stimulation (HF-rTMS), and sham stimulation-for treating cognitive deficits in treatment-resistant schizophrenia. Ninety patients receiving clozapine will be randomized 1:1:1 to receive 20 sessions over 4 weeks targeting the dorsolateral prefrontal cortex. The primary outcome is change in cognitive function measured by B-CATS score at 2, 4, and 12 weeks. Secondary outcomes include social cognition, symptom severity, brain metabolism (FDG-PET), and inflammatory biomarkers.
Key Dates
- First listed
- Mar 3, 2026
- Start date
- Feb 15, 2026
- Status verified
- Feb 2026
- Primary completion
- Feb 14, 2029
- Completion
- Dec 14, 2029
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Accelerated iTBS* Participants will receive aITBS using 100X transcranial magnetic stimulator with 70 mm active cooled figure-of-eight coil * Parameters: 3 pulses at 50 Hz bursts, 2 sec on/10 sec off, 3 minutes per session * Dosage: 1800 pulses per day (3 rounds separated by 15 min), 5 days/week for 4 weeks
- Active Comparator: High-Frequency rTMS* Participants will receive HF-rTMS using 100X transcranial magnetic stimulator with 70 mm active cooled figure-of-eight coil * Parameters: 20 Hz pulses, 20 minutes, 4 sec per second, intertrain interval 20 sec, 110% RMT * Dosage: 5 sessions per week for 4 weeks
- Sham Comparator: Sham rTMS* Participants will receive sham stimulation using identical-appearing sham coil * Same session schedule and positioning as active groups but without therapeutic magnetic field
Primary Outcome Measure
Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) [ Time Frame: Baseline, 2 weeks, 4 weeks, 12 weeks ]
Central Contacts
- Debadatta Mohapatra, MD+91 9437658251
Related Studies
- Toward a Computationally-Informed, Personalized Treatment for HallucinationsEARLY_PHASE1 · Recruiting · Yale University · New Haven, Connecticut
- Normobaric Oxygen Therapy for Individuals With First-Episode PsychosisRecruiting · Nicholas Breitborde · Columbus, Ohio
- Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental IllnessRecruiting · Massachusetts General Hospital · Charlestown, Massachusetts
- Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis RiskRecruiting · Northwell Health · Glen Oaks, New York